Clinical Trial Detail

NCT ID NCT01545947
Title Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications

lung non-small cell carcinoma

Therapies

Azacitidine + Onatasertib

Erlotinib + Onatasertib

Age Groups: adult

No variant requirements are available.